Key result
Experimental TMVR with LAMPOON leads to acute prosthesis-related hemolytic anemia in severe mitral annular calcification.
Why the study?
Mitral valve disease with extensive mitral annular calcification poses surgical challenges, and transcatheter mitral valve replacement faces ongoing complications like paravalvular leak, left ventricular outflow tract obstruction, and hemolysis.
Case Report (n=1)
TMVR in the setting of severe MAC remains a high-risk procedure complicated by potentially life-threatening adverse events such as acute hemolytic anemia, emphasizing the need for improved device design and rigorous patient selection.
Alerts to hemolytic anemia risk after TMVR in severe MAC; leaves open optimal patient selection and device refinements.
Mitral valve disease, particularly in the context of extensive mitral annular calcification (MAC), poses significant challenges for traditional surgical management. Transcatheter mitral valve replacement (TMVR) has emerged as a promising alternative for high-risk and inoperable patients, driven by rapid advancements in valve technology, imaging techniques, and procedural strategies. Nevertheless, complications such as paravalvular leak (PVL), left ventricular outflow tract (LVOT) obstruction, and hemolysis remain obstacles to optimal outcomes, particularly in patients with complex annular anatomy. We present the case of an 89-year-old female with severe mitral stenosis and MAC who developed acute hemolytic anemia following experimental TMVR using the Edwards SAPIEN S3 valve. This case serves as a platform to explore recent advances in TMVR, including novel device platforms, enhanced imaging modalities for pre-procedural planning, innovative deployment strategies, and emerging adjunctive techniques aimed at reducing complications. Through this case, we underscore persistent challenges and emphasize the importance of meticulous patient selection and vigilant follow-up. Despite substantial progress, TMVR in the setting of MAC remains high-risk, demanding continued innovation in valve design, refined patient stratification, and improved peri-procedural management to enhance outcomes and mitigate risks such as hemolysis.
No takes yet. Share an insight, caveat, or question.
Fongrat et al. (2025) conducted a case report in Severe mitral stenosis with extensive mitral annular calcification (n=1). Transcatheter mitral valve replacement (TMVR) was evaluated on Development of post-procedural acute hemolytic anemia. An 89-year-old woman with severe mitral annular calcification developed acute prosthesis-related hemolytic anemia shortly after undergoing experimental transcatheter mitral valve replacement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: